

General Assembly

Amendment

January Session, 2011

LCO No. 8014

SB0101508014SR0

Offered by:

SEN. BOUCHER, 26th Dist.

To: Senate Bill No. **1015** File No. 605 Cal. No. 375

"AN ACT CONCERNING THE PALLIATIVE USE OF MARIJUANA."

1 After the last section, add the following and renumber sections and 2 internal references accordingly:

3 "Sec. 501. (NEW) (Effective October 1, 2011) (a) The Commissioner of 4 Consumer Protection shall establish a palliative marijuana review 5 panel consisting of seven physicians or surgeons who are 6 knowledgeable about the palliative use of marijuana and certified by 7 the appropriate American board in one of the following specialties: 8 Neurology, pain medicine, pain management, medical oncology, 9 psychiatry, infectious disease, family medicine or gynecology. The 10 commissioner shall select the members from a list submitted by the 11 Connecticut Medical Society. Four of the members of the panel first 12 appointed shall serve for a term of four years and three of the members of the panel first appointed shall serve for a term of three years. 13 14 Thereafter, members of the panel shall serve for a term of four years 15 and shall be eligible for reappointment. Any member of the panel may 16 serve until a successor is appointed. At the first meeting of the panel,

- 17 the panel shall select a chairperson from among its members.
- 18 (b) A quorum of the palliative marijuana review panel shall consist 19 of four members.
 - (c) Prior to signing a written certification on behalf of a qualifying patient, a physician shall submit, on such form as the review panel prescribes, such physician's opinion that a qualifying patient has a debilitating medical condition and the potential benefits of the palliative use of marijuana would likely outweigh the health risks of such use to the qualifying patient. The palliative marijuana review panel shall review such opinion and determine whether the board agrees that the qualifying patient has a debilitating medical condition and the potential benefits of the palliative use of marijuana would likely outweigh the health risks of such use to the qualifying patient. The panel shall complete its review within thirty days after receiving such form, and shall notify such physician and the Commissioner of Consumer Protection in writing whether the board agrees with such physician's opinion not later than five business days after completing its review. The physician shall not sign a written certification unless the panel agrees with such physician's opinion pursuant to such review.
 - (d) The decision of the panel under this section shall be final and a review under this section shall not be deemed a contested case, as defined in section 4-166 of the general statutes, except that nothing in this section shall prohibit a physician from submitting a form with supplemental information on behalf of a qualifying patient after a determination by the panel that the panel does not agree with the physician's opinion that the qualifying patient has a debilitating medical condition and the potential benefits of the palliative use of marijuana would likely outweigh the health risks of such use to the qualifying patient.
 - (e) Any information submitted to the board pursuant to this section shall be confidential and shall not be subject to disclosure under the

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Freedom of Information Act, as defined in section 1-200 of the general statutes.

Sec. 502. (NEW) (Effective October 1, 2011) Notwithstanding the provisions of subsection (a) of section 3 of this act, a registration certificate shall expire six months from the date of issuance unless the written certification indicates that the qualifying patient has a terminal illness, in which case such registration certificate shall be effective until the expiration of such written certification. For the purposes of this section, "terminal illness" means an active and progressive illness that results in a patient being diagnosed by a physician as having a prognosis of six months or less to live.

Sec. 503. (NEW) (Effective October 1, 2011) No physician may issue a written certification to a qualifying patient for the palliative use of marijuana unless the physician has been certified to issue such written certifications pursuant to this section. The Commissioner of Consumer Protection shall adopt regulations, in accordance with chapter 54 of the general statutes, to establish a procedure and criteria for certifying physicians to issue written certifications to qualifying patients for the palliative use of marijuana. Such regulations shall provide that no physician may be certified to issue such written certifications unless the physician demonstrates to the satisfaction of the commissioner that (1) the physician has received training or certification in the treatment of substance abusive or dependent persons, and (2) the physician has adequate knowledge about the physiological effects of marijuana, the side effects of marijuana and the interaction of marijuana with other drugs.

Sec. 504. (NEW) (*Effective October 1, 2011*) The Commissioner of Consumer Protection shall adopt regulations, in accordance with chapter 54 of the general statutes, to establish a standard of care for the palliative use of marijuana. At a minimum, such standard of care shall:

(1) Require that a physician issuing a written certification document that the qualifying patient has tried all conventional medical

treatments and that such medical treatments have failed to provide the desired relief;

- (2) Require that a physician issuing a written certification obtain written informed consent from a qualifying patient concerning the medical risks of the use of marijuana, and provide that such informed consent shall include information about the risk of infection, pulmonary complications, suppression of immune function, impairment of driving and other motor skills and habituation;
- (3) Require that prior to issuing a written certification, each physician document in the qualifying patient's medical record such qualifying patient's history, if any, of abusing marijuana or any other psychoactive or addictive controlled substance;
- (4) Provide that during any period when a qualifying patient holds an effective registration certificate pursuant to subsection (a) of section 3 of this act, the qualifying patient shall be subject to periodic chemical analysis of such qualifying patient's blood, breath or urine for the purpose of determining whether the qualifying patient has ingested, inhaled or otherwise introduced into such qualifying patient's body a controlled substance that has not been prescribed by a physician, and further provide that the Department of Consumer Protection shall revoke a registration certificate for any qualifying patient who fails to comply with such testing requirement, or for whom such analysis indicates the presence of a controlled substance that has not been prescribed by a physician;
- (5) Provide that during any period when a qualifying patient holds an effective registration certificate pursuant to subsection (a) of section 3 of this act, the qualifying patient shall be subject to periodic medical examinations on such schedule and in such manner as prescribed in such regulations, and further provide that such medical examinations shall include, but need not be limited to, pulmonary function testing, evaluation of immune system function and testing to determine whether a superadded infection is present;

113 (6) Establish procedures to ensure the standardization of the 114 tetrahydrocannabinol potency, and the absence of microbial 115 contaminants, in marijuana used by qualifying patients;

- (7) Establish specific criteria for a physician to use when (A) issuing a written certification to a qualifying patient who presents with a debilitating medical condition, and (B) determining the appropriate duration of palliative use of marijuana with respect to such qualifying patient and debilitating medical condition;
- 121 (8) Provide that the Department of Consumer Protection shall not 122 issue a registration certificate pursuant to subsection (a) of section 3 of 123 this act for a duration that exceeds the duration established pursuant 124 to subparagraph (B) of subdivision (7) of this section; and
- 125 (9) Establish a state-wide tracking system related to the palliative 126 use of marijuana.
- Sec. 505. (NEW) (*Effective October 1, 2011*) (a) The Department of Consumer Protection shall establish an investigational review board to:
- 130 (1) Monitor the issuance of written certifications to qualifying 131 patients to ensure that physicians follow the guidelines set forth in the 132 standard of care established in section 504 of this act when issuing 133 such written certifications;
- 134 (2) Conduct a study or clinical trial consisting of all qualifying 135 patients who hold valid registration certificates pursuant to section 3 of 136 this act in order to research the potential therapeutic benefits of 137 marijuana; and
- (3) Establish procedures to require physicians who issue written certifications to provide the board with valid medical research that indicates that marijuana is an effective treatment for the debilitating medical condition for which the written certification is issued.
- 142 (b) The Commissioner of Consumer Protection shall adopt

regulations, in accordance with chapter 54 of the general statutes, to implement the provisions of this section. On and after the date such regulations are effective, each physician who issues a written certification shall submit information to the board in the manner prescribed in such regulations."